How druggable is protein kinase CK2?

Medicinal Research Reviews

Volumn 30, Issue 3, 2010, Pages 419-462

  Cozza, Giorgio ^a   Bortolato, Andrea ^a   Moro, Stefano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Protein kinase CK2

Indexed keywords

AMINO ACID; ANTHRAQUINONE; BENZIMIDAZOLE DERIVATIVE; CARBOXYL GROUP; CASEIN KINASE 2 INHIBITOR; CASEIN KINASE II; COUMARIN; ELLAGIC ACID; ENZYME INHIBITOR; FLAVONOID; FLUORENONE DERIVATIVE; HOLOENZYME; UNCLASSIFIED DRUG; XANTHENE;

CATALYSIS; DRUG SELECTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; MAMMAL CELL; NONHUMAN; PHYLOGENY; PROTEIN TARGETING; REVIEW;

AMINO ACIDS; ANIMALS; BINDING SITES; CASEIN KINASE II; CELL NUCLEUS; CRYSTALLOGRAPHY, X-RAY; CYTOSOL; HOLOENZYMES; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEOME; PROTEOMICS; RATS;

EID: 77951980137     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20164     Document Type: Review

References (198)

1. Burnett G, Kennedy EP. The enzymatic phosphorylation of proteins. J Biol Chem 1954;211:969-980.
2. Pinna LA. Protein kinase CK2: A challenge to canons. J Cell Sci 2002;115:3873-3878.
3. Litchfield DW, Bosc DG, Canton DA, Saulnier RB, Vilk G, Zhang C. Functional specialization of CK2 isoforms and characterization of isoform-specific binding partners. Mol Cell Biochem 2001;227:21-29. (Pubitemid 34048365)
4. Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O'Brien C, Seldin DC. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol 2008;28:131-139.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-1934. (Pubitemid 35425239)
6. Sarno S, Vaglio P, Marin O, Issinger OG, Ruffato K, Pinna LA. Mutational analysis of residues implicated in the interaction between protein kinase CK2 and peptide substrates. Biochemistry 1997;36:11717-11724. (Pubitemid 27424096)
7. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-134.
8. Hu E, Rubin CS. Expression of wild-type and mutated forms of the catalytic (alpha) subunit of Caenorhabditis elegans casein kinase II in Escherichia coli. J Biol Chem 1990;265:20609-20615. (Pubitemid 120014051)
9. Gatica M, Jedlicki A, Allende CC, Allende JE. Activity of the E75E76 mutant of the alpha subunit of casein kinase II from Xenopus laevis. FEBS Lett 1994;339:93-96. (Pubitemid 2046965)
10. Sarno S, Vaglio P, Meggio F, Issinger OG, Pinna LA. Protein kinase CK2 mutants defective in substrate recognition. Purification and kinetic analysis. J Biol Chem 1996;271:10595-10601. (Pubitemid 26145793)
11. Sarno S, Vaglio P, Marin O, Meggio F, Issinger OG, Pinna LA. Basic residues in the 74-83 and 191-198 segments of protein kinase CK2 catalytic subunit are implicated in negative but not in positive regulation by the beta-subunit. Eur J Biochem 1997;248:290-295. (Pubitemid 27387469)
12. Vaglio P, Sarno S, Marin O, Meggio F, Issinger OG, Pinna LA. Mapping the residues of protein kinase CK2 alpha subunit responsible for responsiveness to polyanionic inhibitors. FEBS Lett 1996;380:25-28. (Pubitemid 26058727)
13. Johnson LN, Noble ME, Owen DJ. Active and inactive protein kinases: Structural basis for regulation. Cell 1996;85:149-158.
14. Sarno S, Ghisellini P, Pinna LA. Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme. J Biol Chem 2002;277:22509-22514. (Pubitemid 34967224)
15. Marin O, Meggio F, Pinna LA. Design and synthesis of two new peptide substrates for the specific and sensitive monitoring of casein kinases-1 and -2. Biochem Biophys Res Commun 1994;198:898-905. (Pubitemid 24172782)
16. Niefind K, Putter M, Guerra B, Issinger OG, Schomburg D. GTP plus water mimic ATP in the active site of protein kinase CK2. Nat Struct Biol 1999;6:1100-1103.
17. Livak KJ. Detailed structure of the Drosophila melanogaster stellate genes and their transcripts. Genetics 1990;124:303-316. (Pubitemid 20066100)
18. Chantalat L, Leroy D, Filhol O, Nueda A, Benitez MJ, Chambaz EM, Cochet C, Dideberg O. Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger-mediated dimerization. EMBO J 1999;18:2930-2940. (Pubitemid 29255602)
19. Raaf J, Brunstein E, Issinger OG, Niefind K. The interaction of CK2alpha and CK2beta, the subunits of protein kinase CK2, requires CK2beta in a preformed conformation and is enthalpically driven. Protein Sci 2008;17:2180-2186.
20. Boldyreff B, Meggio F, Pinna LA, Issinger OG. Reconstitution of normal and hyperactivated forms of casein kinase-2 by variably mutated beta-subunits. Biochemistry 1993;32:12672-12677. (Pubitemid 24005864)
21. Meggio F, Boldyreff B, Issinger OG, Pinna LA. Casein kinase 2 down-regulation and activation by polybasic peptides are mediated by acidic residues in the 55-64 region of the beta-subunit. A study with calmodulin as phosphorylatable substrate. Biochemistry 1994;33:4336-4342.
22. Lin WJ, Sheu GT, Traugh JA. Effects of autophosphorylation on casein kinase II activity: Evidence from mutations in the beta subunit. Biochemistry 1994;33:6998-7004.
23. Boldyreff B, Meggio F, Pinna LA, Issinger OG. Efficient autophosphorylation and phosphorylation of the beta-subunit by casein kinase-2 require the integrity of an acidic cluster 50 residues downstream from the phosphoacceptor site. J Biol Chem 1994;269:4827-4831. (Pubitemid 24239456)
24. Leroy D, Filhol O, Delcros JG, Pares S, Chambaz EM, Cochet C. Chemical features of the protein kinase CK2 polyamine binding site. Biochemistry 1997;36:1242-1250. (Pubitemid 27074948)
25. Boldyreff B, Mietens U, Issinger OG. Structure of protein kinase CK2: Dimerization of the human beta-subunit. FEBS Lett 1996;379:153-156. (Pubitemid 26037844)
26. Qian X, Gozani SN, Yoon H, Jeon CJ, Agarwal K, Weiss MA. Novel zinc finger motif in the basal transcriptional machinery: Three-dimensional NMR studies of the nucleic acid binding domain of transcriptional elongation factor TFIIS. Biochemistry 1993;32:9944-9959. (Pubitemid 23312420)
27. Wang B, Jones DN, Kaine BP, Weiss MA. High-resolution structure of an archaeal zinc ribbon defines a general architectural motif in eukaryotic RNA polymerases. Structure 1998;6:555-569. (Pubitemid 28262546)
28. Olsen BB, Guerra B. Ability of CK2beta to selectively regulate cellular protein kinases. Mol Cell Biochem 2008;316:115-126.
29. Chen M, Cooper JA. The beta subunit of CKII negatively regulates Xenopus oocyte maturation. Proc Natl Acad Sci USA 1997;94:9136-9140. (Pubitemid 27357795)
30. Lieberman SL, Ruderman JV. CK2 beta, which inhibits Mos function, binds to a discrete domain in the N-terminus of Mos. Dev Biol 2004;268:271-279.
31. Boldyreff B, Issinger OG. A-Raf kinase is a new interacting partner of protein kinase CK2 beta subunit. FEBS Lett 1997;403:197-199. (Pubitemid 27081493)
32. Hagemann C, Kalmes A, Wixler V, Wixler L, Schuster T, Rapp UR. The regulatory subunit of protein kinase CK2 is a specific A-Raf activator. FEBS Lett 1997;403:200-202. (Pubitemid 27081494)
33. Kusk M, Ahmed R, Thomsen B, Bendixen C, Issinger OG, Boldyreff B. Interactions of protein kinase CK2beta subunit within the holoenzyme and with other proteins. Mol Cell Biochem 1999;191:51-58. (Pubitemid 29092710)
34. Guerra B, Issinger OG, Wang JY. Modulation of human checkpoint kinase Chk1 by the regulatory beta-subunit of protein kinase CK2. Oncogene 2003;22:4933-4942. (Pubitemid 37026392)
35. O'Brien KA, Lemke SJ, Cocke KS, Rao RN, Beckmann RP. Casein kinase 2 binds to and phosphorylates BRCA1. Biochem Biophys Res Commun 1999;260:658-664.
36. Tchernev VT, Mansfield TA, Giot L, Kumar AM, Nandabalan K, Li Y, Mishra VS, Detter JC, Rothberg JM, Wallace MR, Southwick FS, Kingsmore SF. The Chediak-Higashi protein interacts with SNARE complex and signal transduction proteins. Mol Med 2002;8:56-64. (Pubitemid 34451121)
37. Kim YS, Lee JH, Park JW, Bae YS. Regulation of protein kinase CKII by direct interaction with the C-terminal region of p47(phox). Biochem Biophys Res Commun 2001;286:87-93.
38. Dobrowolska G, Meggio F, Szczegielniak J, Muszynska G, Pinna LA. Purification and characterization of maize seedling casein kinase IIB, a monomeric enzyme immunologically related to the alpha subunit of animal casein kinase-2. Eur J Biochem 1992;204:299-303.
39. Kikkawa U, Mann SK, Firtel RA, Hunter T. Molecular cloning of casein kinase II alpha subunit from Dictyostelium discoideum and its expression in the life cycle. Mol Cell Biol 1992;12:5711-5723.
40. Niefind K, Guerra B, Ermakowa I, Issinger OG. Crystal structure of human protein kinase CK2: Insights into basic properties of the CK2 holoenzyme. EMBO J 2001;20:5320-5331. (Pubitemid 32959451)
41. Gietz RD, Graham KC, Litchfield DW. Interactions between the subunits of casein kinase II. J Biol Chem 1995;270:13017-13021.
42. Meggio F, Boldyreff B, Marin O, Pinna LA, Issinger OG. Role of the beta subunit of casein kinase-2 on the stability and specificity of the recombinant reconstituted holoenzyme. Eur J Biochem 1992;204:293-297.
43. Antonelli M, Daniotti JL, Rojo D, Allende CC, Allende JE. Cloning, expression and properties of the alpha′ subunit of casein kinase 2 from zebrafish (Danio rerio). Eur J Biochem 1996;241:272-279.
44. Boldyreff B, James P, Staudenmann W, Issinger OG. Ser2 is the autophosphorylation site in the beta subunit from bicistronically expressed human casein kinase-2 and from native rat liver casein kinase-2 beta. Eur J Biochem 1993;218:515-521. (Pubitemid 24003768)
45. Litchfield DW, Lozeman FJ, Cicirelli MF, Harrylock M, Ericsson LH, Piening CJ, Krebs EG. Phosphorylation of the beta subunit of casein kinase II in human A431 cells. Identification of the autophosphorylation site and a site phosphorylated by p34cdc2. J Biol Chem 1991;266:20380-20389. (Pubitemid 21908470)
46. Bodenbach L, Fauss J, Robitzki A, Krehan A, Lorenz P, Lozeman FJ, Pyerin W. Recombinant human casein kinase II. A study with the complete set of subunits (alpha, alpha′ and beta), site-directed autophosphorylation mutants and a bicistronically expressed holoenzyme. Eur J Biochem 1994;220:263-273. (Pubitemid 24067577)
47. Meggio F, Pinna LA. Subunit structure and autophosphorylation mechanism of casein kinase-TS (type-2) from rat liver cytosol. Eur J Biochem 1984;145:593-599. (Pubitemid 15178132)
48. Pagano MA, Sarno S, Poletto G, Cozza G, Pinna LA, Meggio F. Autophosphorylation at the regulatory beta subunit reflects the supramolecular organization of protein kinase CK2. Mol Cell Biochem 2005;274:23-29. (Pubitemid 41001496)
49. Glover CV. A filamentous form of Drosophila casein kinase II. J Biol Chem 1986;261:14349-14354.
50. Valero E, De Bonis S, Filhol O, Wade RH, Langowski J, Chambaz EM, Cochet C. Quaternary structure of casein kinase 2. Characterization of multiple oligomeric states and relation with its catalytic activity. J Biol Chem 1995;270:8345-8352.
51. Olsen BB, Rasmussen T, Niefind K, Issinger OG. Biochemical characterization of CK2alpha and alpha′ paralogues and their derived holoenzymes: Evidence for the existence of a heterotrimeric CK2alpha′- holoenzyme forming trimeric complexes. Mol Cell Biochem 2008;316:37-47.
52. Wilson LK, Dhillon N, Thorner J, Martin GS. Casein kinase II catalyzes tyrosine phosphorylation of the yeast nucleolar immunophilin Fpr3. J Biol Chem 1997;272:12961-12967. (Pubitemid 27216712)
53. Marin O, Meggio F, Sarno S, Cesaro L, Pagano MA, Pinna LA. Tyrosine versus serine/threonine phosphorylation by protein kinase casein kinase-2. A study with peptide substrates derived from immunophilin Fpr3. J Biol Chem 1999;274:29260-29265. (Pubitemid 29477092)
54. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003;17:349-368.
55. Bojanowski K, Filhol O, Cochet C, Chambaz EM, Larsen AK. DNA topoisomerase II and casein kinase II associate in a molecular complex that is catalytically active. J Biol Chem 1993;268:22920-22926. (Pubitemid 23318358)
56. Li D, Meier UT, Dobrowolska G, Krebs EG. Specific interaction between casein kinase 2 and the nucleolar protein Nopp140. J Biol Chem 1997;272:3773-3779. (Pubitemid 27066887)
57. Filhol O, Baudier J, Delphin C, Loue-Mackenbach P, Chambaz EM, Cochet C. Casein kinase II and the tumor suppressor protein P53 associate in a molecular complex that is negatively regulated upon P53 phosphorylation. J Biol Chem 1992;267:20577-20583.
58. Poletto G, Vilardell J, Marin O, Pagano MA, Cozza G, Sarno S, Falques A, Itarte E, Pinna LA, Meggio F. The regulatory beta subunit of protein kinase CK2 contributes to the recognition of the substrate consensus sequence. A study with an eIF2 beta-derived peptide. Biochemistry 2008;47:8317-8325.
59. Bonnet H, Filhol O, Truchet I, Brethenou P, Cochet C, Amalric F, Bouche G. Fibroblast growth factor-2 binds to the regulatory beta subunit of CK2 and directly stimulates CK2 activity toward nucleolin. J Biol Chem 1996;271:24781-24787. (Pubitemid 26333225)
60. Marin O, Sarno S, Boschetti M, Pagano MA, Meggio F, Ciminale V, D'Agostino DM, Pinna LA. Unique features of HIV-1 Rev protein phosphorylation by protein kinase CK2 ("casein kinase-2"). FEBS Lett 2000;481:63-67. (Pubitemid 30662378)
61. Meggio F, Boldyreff B, Marin O, Marchiori F, Perich JW, Issinger OG, Pinna LA. The effect of polylysine on casein-kinase-2 activity is influenced by both the structure of the protein/peptide substrates and the subunit composition of the enzyme. Eur J Biochem 1992;205:939-945.
62. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: An emerging role for protein kinase CK2. Trends Cell Biol 2002;12:226-230. (Pubitemid 34327615)
63. Ghavidel A, Schultz MC. TATA binding protein-associated CK2 transduces DNA damage signals to the RNA polymerase III transcriptional machinery. Cell 2001;106:575-584. (Pubitemid 32879319)
64. Padmanabha R, Chen-Wu JL, Hanna DE, Glover CV. Isolation, sequencing, and disruption of the yeast CKA2 gene: Casein kinase II is essential for viability in Saccharomyces cerevisiae. Mol Cell Biol 1990;10:4089-4099. (Pubitemid 20227291)
65. Xu X, Rich ES, Jr., Seldin DC. Murine protein kinase CK2 alpha0: cDNA and genomic cloning and chromosomal mapping. Genomics 1998;48:79-86. (Pubitemid 28110804)
66. Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB, Cochet C, Issinger OG, Boldyreff B. Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 2003;23:908-915. (Pubitemid 36133509)
67. Glover CV, 3rd. On the physiological role of casein kinase II in Saccharomyces cerevisiae. Prog Nucleic Acid Res Mol Biol 1998;59:95-133.
68. Toczyski DP, Galgoczy DJ, Hartwell LH. CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell 1997;90:1097-1106.
69. Ishii A, Nonaka T, Taniguchi S, Saito T, Arai T, Mann D, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M. Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. FEBS Lett 2007;581:4711-4717. (Pubitemid 47418797)
70. Guerra B, Issinger OG. Protein kinase CK2 in human diseases. Curr Med Chem 2008;15:1870-1886.
71. Sarno S, Pinna LA. Protein kinase CK2 as a druggable target. Mol Biosyst 2008;4:889-894.
72. Iimoto DS, Masliah E, DeTeresa R, Terry RD, Saitoh T. Aberrant casein kinase II in Alzheimer's disease. Brain Res 1990;507:273-280. (Pubitemid 20054109) (Pubitemid 20054109)
73. Aksenova MV, Burbaeva GS, Kandror KV, Kapkov DV, Stepanov AS. The decreased level of casein kinase 2 in brain cortex of schizophrenic and Alzheimer's disease patients. FEBS Lett 1991;279:55-57.
74. Masliah E, Iimoto DS, Mallory M, Albright T, Hansen L, Saitoh T. Casein kinase II alteration precedes tau accumulation in tangle formation. Am J Pathol 1992;140:263-268.
75. Greenwood JA, Scott CW, Spreen RC, Caputo CB, Johnson GV. Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert. Identification of threonine 39 as the primary phosphate acceptor. J Biol Chem 1994;269:4373-4380. (Pubitemid 24237803)
76. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 2000;275:390-397. (Pubitemid 30038997)
77. Lee G, Tanaka M, Park K, Lee SS, Kim YM, Junn E, Lee SH, Mouradian MM. Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J Biol Chem 2004;279:6834-6839. (Pubitemid 38248825)
78. Ryu MY, Kim DW, Arima K, Mouradian MM, Kim SU, Lee G. Localization of CKII beta subunits in Lewy bodies of Parkinson's disease. J Neurol Sci 2008;266:9-12. (Pubitemid 351186510)
79. Chen J, Gao C, Shi Q, Wang G, Lei Y, Shan B, Zhang B, Dong C, Shi S, Wang X, Tian C, Han J, Dong X. Casein kinase II interacts with prion protein in vitro and forms complex with native prion protein in vivo. Acta Biochim Biophys Sin 2008;40:1039-1047.
80. Jones S, Yakel JL. Casein kinase ii (protein kinase ck2) regulates serotonin 5-ht(3) receptor channel function in ng108-15 cells. Neuroscience 2003;119:629-634.
81. Boehning D, Moon C, Sharma S, Hurt KJ, Hester LD, Ronnett GV, Shugar D, Snyder SH. Carbon monoxide neurotransmission activated by CK2 phosphorylation of heme oxygenase-2. Neuron 2003;40:129-137. (Pubitemid 37222468)
82. Quadroni M, L'Hostis EL, Corti C, Myagkikh I, Durussel I, Cox J, James P, Carafoli E. Phosphorylation of calmodulin alters its potency as an activator of target enzymes. Biochemistry 1998;37:6523-6532. (Pubitemid 28213673)
83. Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension 2005;45:126-132. (Pubitemid 40066426)
84. Kohlstedt K, Shoghi F, Muller-Esterl W, Busse R, Fleming I. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res 2002;91:749-756. (Pubitemid 35204958)
85. Yamada M, Katsuma S, Adachi T, Hirasawa A, Shiojima S, Kadowaki T, Okuno Y, Koshimizu TA, Fujii S, Sekiya Y, Miyamoto Y, Tamura M, Yumura W, Nihei H, Kobayashi M, Tsujimoto G. Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis. Proc Natl Acad Sci USA 2005;102:7736-7741. (Pubitemid 40741040)
86. Hildebrandt F, Otto E. Molecular genetics of nephronophthisis and medullary cystic kidney disease. J Am Soc Nephrol 2000;11:1753-1761.
87. Schermer B, Hopker K, Omran H, Ghenoiu C, Fliegauf M, Fekete A, Horvath J, Kottgen M, Hackl M, Zschiedrich S, Huber TB, Kramer-Zucker A, Zentgraf H, Blaukat A, Walz G, Benzing T. Phosphorylation by casein kinase 2 induces PACS-1 binding of nephrocystin and targeting to cilia. EMBO J 2005;24:4415-4424. (Pubitemid 41828915)
88. Axtell RC, Xu L, Barnum SR, Raman C. CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis: Protection is associated with diminished populations of IL-17-expressing T cells in the central nervous system. J Immunol 2006;177:8542-8549. (Pubitemid 44893816)
89. Maekawa T, Kosuge S, Karino A, Okano T, Ito J, Munakata H, Ohtsuki K. Biochemical characterization of 60S acidic ribosomal P proteins from porcine liver and the inhibition of their immunocomplex formation with sera from systemic lupus erythematosus (SLE) patients by glycyrrhizin in vitro. Biol Pharm Bull 2000;23:27-32. (Pubitemid 30077788)
90. Caponi L, Anzilotti C, Longombardo G, Migliorini P. Antibodies directed against ribosomal P proteins cross-react with phospholipids. Clin Exp Immunol 2007;150:140-143. (Pubitemid 47383298)
91. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-866.
92. Harvey EJ, Li N, Ramji DP. Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-gamma-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:806-812. (Pubitemid 46606710)
93. Widder JD, Chen W, Li L, Dikalov S, Thony B, Hatakeyama K, Harrison DG. Regulation of tetrahydrobiopterin biosynthesis by shear stress. Circ Res 2007;101:830-838. (Pubitemid 350287198)
94. Dunzendorfer S, Lee HK, Tobias PS. Flow-dependent regulation of endothelial Toll-like receptor 2 expression through inhibition of SP1 activity. Circ Res 2004;95:684-691. (Pubitemid 39331928)
95. Hubert A, Paris S, Piret JP, Ninane N, Raes M, Michiels C. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. J Cell Sci 2006;119:3351-3362. (Pubitemid 44405220)
96. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992;71:875-886.
97. Mottet D, Ruys SP, Demazy C, Raes M, Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer 2005;117:764-774. (Pubitemid 41598827)
98. Pluemsampant S, Safronova OS, Nakahama K, Morita I. Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Int J Cancer 2008;122:333-341. (Pubitemid 350234719)
99. Kramerov AA, Saghizadeh M, Pan H, Kabosova A, Montenarh M, Ahmed K, Penn JS, Chan CK, Hinton DR, Grant MB, Ljubimov AV. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol 2006;168:1722-1736.
100. Ljubimov AV, Caballero S, Aoki AM, Pinna LA, Grant MB, Castellon R. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci 2004;45:4583-4591. (Pubitemid 39564687)
101. Huang KP, Itarte E, Singh TJ, Akatsuka A. Phosphorylation of glycogen synthase by cyclic AMP-independent casein kinase-2 from rabbit skeletal muscle. J Biol Chem 1982;257:3236-3242.
102. Hauck L, Harms C, An J, Rohne J, Gertz K, Dietz R, Endres M, von Harsdorf R. Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat Med 2008;14:315-324.
103. Tapia JC, Bolanos-Garcia VM, Sayed M, Allende CC, Allende JE. Cell cycle regulatory protein p27KIP1 is a substrate and interacts with the protein kinase CK2. J Cell Biochem 2004;91:865-879.
104. Maeda R, Raz I, Zurlo F, Sommercorn J. Activation of skeletal muscle casein kinase II by insulin is not diminished in subjects with insulin resistance. J Clin Invest 1991;87:1017-1022.
105. Metallo A, Villa-Moruzzi E. Protein phosphatase-1 and -2A, kinase FA, and casein kinase II in skeletal muscle of streptozotocin diabetic rats. Arch Biochem Biophys 1991;289:382-386.
106. Kim SO, Hasham MI, Katz S, Pelech SL. Insulin-regulated protein kinases during postnatal development of rat heart. J Cell Biochem 1998;71:328-339. (Pubitemid 28516324)
107. Chien WM, Parker JN, Schmidt-Grimminger DC, Broker TR, Chow LT. Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry. Cell Growth Differ 2000;11:425-435.
108. Massimi P, Banks L. Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle. Virology 2000;276:388-394.
109. Medina-Palazon C, Gruffat H, Mure F, Filhol O, Vingtdeux-Didier V, Drobecq H, Cochet C, Sergeant N, Sergeant A, Manet E. Protein kinase CK2 phosphorylation of EB2 regulates its function in the production of Epstein-Barr virus infectious viral particles. J Virol 2007;81:11850-11860. (Pubitemid 47623817)
110. Bryant HE, Matthews DA, Wadd S, Scott JE, Kean J, Graham S, Russell WC, Clements JB. Interaction between herpes simplex virus type 1 IE63 protein and cellular protein p32. J Virol 2000;74:11322-11328. (Pubitemid 32224002)
111. Koffa MD, Kean J, Zachos G, Rice SA, Clements JB. CK2 protein kinase is stimulated and redistributed by functional herpes simplex virus ICP27 protein. J Virol 2003;77:4315-4325. (Pubitemid 36350970)
112. Jensen BC, Kifer CT, Brekken DL, Randall AC, Wang Q, Drees BL, Parsons M. Characterization of protein kinase CK2 from Trypanosoma brucei. Mol Biochem Parasitol 2007;151:28-40. (Pubitemid 44880450)
113. Park JH, Brekken DL, Randall AC, Parsons M. Molecular cloning of Trypanosoma brucei CK2 catalytic subunits: The alpha isoform is nucleolar and phosphorylates the nucleolar protein Nopp44/46. Mol Biochem Parasitol 2002;119:97-106. (Pubitemid 34038029)
114. Silva-Neto MA, Carneiro AB, Vieira DP, Mesquita RD, Lopes AH. Platelet-activating factor (PAF) activates casein kinase 2 in the protozoan parasite Herpetomonas muscarum muscarum. Biochem Biophys Res Commun 2002;293:1358-1363.
115. Vieira LL, Sacerdoti-Sierra N, Jaffe CL. Effect of pH and temperature on protein kinase release by Leishmania donovani. Int J Parasitol 2002;32:1085-1093. (Pubitemid 34761902)
116. Tarrab-Hazdai R, Hanoch T, Jeon SH, Pauli H, Gold D, Arnon R, Seger R. Ecto- and exoprotein kinases in Schistosoma mansoni: Regulation of surface phosphorylation by acetylcholine and identification of the alpha subunit of CKII as a major secreted protein kinase. J Parasitol 2005;91:756-763. (Pubitemid 41324752)
117. Hora R, Bridges DJ, Craig A, Sharma A. Erythrocytic casein kinase II regulates cytoadherence of Plasmodium falciparum infected red blood cells. J Biol Chem 2009;284:6260-6269.
118. Holland Z, Prudent R, Reiser JB, Cochet C, Doerig C. Functional analysis of protein kinase CK2 of the human malaria parasite Plasmodium falciparum. Eukaryot Cell 2009;8:388-397.
119. Heriche JK, Chambaz EM. Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases. Oncogene 1998;17:13-18.
120. Mishra S, Reichert A, Cunnick J, Senadheera D, Hemmeryckx B, Heisterkamp N, Groffen J. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003;22:8255-8262. (Pubitemid 37485518)
121. Homma MK, Li D, Krebs EG, Yuasa Y, Homma Y. Association and regulation of casein kinase 2 activity by adenomatous polyposis coli protein. Proc Natl Acad Sci USA 2002;99:5959-5964. (Pubitemid 34493247)
122. Seitz G, Munstermann U, Schneider HR, Issinger OG. Characterization of casein kinase II in human colonic carcinomas after heterotransplantation into nude mice. Biochem Biophys Res Commun 1989;163:635-641. (Pubitemid 19227353)
123. Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein downregulation in MCF-7 cells. Br J Pharmacol 2001;133:467-476. (Pubitemid 32591912)
124. Munstermann U, Fritz G, Seitz G, Lu YP, Schneider HR, Issinger OG. Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur J Biochem 1990;189:251-257. (Pubitemid 20146007)
125. Yde CW, Frogne T, Lykkesfeldt AE, Fichtner I, Issinger OG, Stenvang J. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett 2007;256:229-237. (Pubitemid 47418349) (Pubitemid 47418349)
126. Guo C, Yu S, Davis AT, Wang H, Green JE, Ahmed K. A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J Biol Chem 2001;276:5992-5999. (Pubitemid 37385757)
127. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2004;2:712-721.
128. Wang G, Ahmad KA, Ahmed K. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res 2006;66:2242-2249. (Pubitemid 43294936)
129. Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K. Downregulation of CK2 induces apoptosis in cancer cells - A potential approach to cancer therapy. Mol Cell Biochem 2005;274:77-84. (Pubitemid 41001503)
130. Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: Association with malignant transformation. Cancer Lett 1996;101:31-35. (Pubitemid 26060189)
131. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, Ahmed K. Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1995;1:659-666.
132. Pagano MA, Arrigoni G, Marin O, Sarno S, Meggio F, Treharne KJ, Mehta A, Pinna LA. Modulation of protein kinase CK2 activity by fragments of CFTR encompassing F508 may reflect functional links with cystic fibrosis pathogenesis. Biochemistry 2008;47:7925-7936.
133. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat Rev Drug Discov 2004;3:935-949. (Pubitemid 39529931)
134. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S, Fagan P, Marvin J, Padilla D, Ravichandran V, Schneider B, Thanki N, Weissig H, Westbrook JD, Zardecki C. The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 2002;58:899-907.
135. Niefind K, Guerra B, Pinna LA, Issinger OG, Schomburg D. Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 A resolution. EMBO J 1998;17:2451-2462. (Pubitemid 28221181) (Pubitemid 28221181)
136. Battistutta R, De Moliner E, Sarno S, Zanotti G, Pinna LA. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci 2001;10:2200-2206. (Pubitemid 32988637)
137. Meggio F, Donella Deana A, Ruzzene M, Brunati AM, Cesaro L, Guerra B, Meyer T, Mett H, Fabbro D, Furet P, Dobrowolska G, Pinnal LA. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem 1995;234:317-322.
138. Bortolato A, Cozza G, Moro S. Protein kinase CK2 inhibitors: Emerging anticancer therapeutic agents? Anticancer Agents Med Chem 2008;8:798-806.
139. Battistutta R, Mazzorana M, Cendron L, Bortolato A, Sarno S, Kazimierczuk Z, Zanotti G, Moro S, Pinna LA. The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules. Chembiochem 2007;8:1804-1809. (Pubitemid 47612869)
140. Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 2007;8:129-139. (Pubitemid 46121580)
141. Sarno S, de Moliner E, Ruzzene M, Pagano MA, Battistutta R, Bain J, Fabbro D, Schoepfer J, Elliott M, Furet P, Meggio F, Zanotti G, Pinna LA. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem J 2003;374:639-646. (Pubitemid 37163909)
142. Prudent R, Moucadel V, Lopez-Ramos M, Aci S, Laudet B, Mouawad L, Barette C, Einhorn J, Einhorn C, Denis JN, Bisson G, Schmidt F, Roy S, Lafanechere L, Florent JC, Cochet C. Expanding the chemical diversity of CK2 inhibitors. Mol Cell Biochem 2008;316:71-85.
143. Meggio F, Pagano MA, Moro S, Zagotto G, Ruzzene M, Sarno S, Cozza G, Bain J, Elliott M, Deana AD, Brunati AM, Pinna LA. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry 2004;43:12931-12936.
144. Sandholt IS, Olsen BB, Guerra B, Issinger OG. Resorufin: A lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 2009;20:238-248.
145. Pagano MA, Bain J, Kazimierczuk Z, Sarno S, Ruzzene M, Di Maira G, Elliott M, Orzeszko A, Cozza G, Meggio F, Pinna LA. The selectivity of inhibitors of protein kinase CK2: An update. Biochem J 2008;415:353-365.
146. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005;115:2618-2624. (Pubitemid 41434384)
147. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007;6:464-479.
148. Richter S, Wenzel A, Stein M, Gabdoulline RR, Wade RC. webPIPSA: A web server for the comparison of protein interaction properties. Nucleic Acids Res 2008;36(Web Server issue):W276-W280.
149. Blomberg N, Gabdoulline RR, Nilges M, Wade RC. Classification of protein sequences by homology modeling and quantitative analysis of electrostatic similarity. Proteins 1999;37:379-387. (Pubitemid 29519728)
150. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc Natl Acad Sci USA 2001;98:10037-10041. (Pubitemid 32802969)
151. Pinna LA, Meggio F. Protein kinase CK2 ("casein kinase-2") and its implication in cell division and proliferation. Prog Cell Cycle Res 1997;3:77-97.
152. Zandomeni R, Zandomeni MC, Shugar D, Weinmann R. Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription. J Biol Chem 1986;261:3414-3419. (Pubitemid 17204962)
153. Lonn U, Lonn S. 5,6-Dichloro-1-beta-O-ribofuranosylbenzimidazole induces DNA damage by interfering with DNA topoisomerase II. Eur J Biochem 1987;164:541-545. (Pubitemid 17072807)
154. Dobrowolska G, Muszynska G, Shugar D. Benzimidazole nucleoside analogues as inhibitors of plant (maize seedling) casein kinases. Biochim Biophys Acta 1991;1080:221-226.
155. Tamm I, Sehgal PB. Halobenzimidazole ribosides and RNA synthesis of cells and viruses. Adv Virus Res 1978;22:187-258. (Pubitemid 9058064)
156. Meggio F, Shugar D, Pinna LA. Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. Eur J Biochem 1990;187:89-94. (Pubitemid 20040364)
157. Andrzejewska M, Pagano MA, Meggio F, Brunati AM, Kazimierczuk Z. Polyhalogenobenzimidazoles: Synthesis and their inhibitory activity against casein kinases. Bioorg Med Chem 2003;11:3997-4002. (Pubitemid 36970127)
158. Pagano MA, Andrzejewska M, Ruzzene M, Sarno S, Cesaro L, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Pinna LA. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem 2004;47:6239-6247.
159. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, Pinna LA. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: A novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 2004;321:1040-1044.
160. Bretner M, Najda-Bernatowicz A, Lebska M, Muszynska G, Kilanowicz A, Sapota A. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole. Mol Cell Biochem 2008;316:87-89.
161. Battistutta R, Mazzorana M, Sarno S, Kazimierczuk Z, Zanotti G, Pinna LA. Inspecting the structure - activity relationship of protein kinase CK2 inhibitors derived from tetrabromobenzimidazole. Chem Biol 2005;12:1211-1219. (Pubitemid 41628256)
162. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ("casein kinase-2"). FEBS Lett 2001;496:44-48.
163. Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 2002;364:41-47.
164. Bortolato A, Moro S. In silico binding free energy predictability by using the linear interaction energy (LIE) method: Bromobenzimidazole CK2 inhibitors as a case study. J Chem Inf Model 2007;47:572-582.
165. Aqvist J, Medina C, Samuelsson JE. A new method for predicting binding affinity in computer-aided drug design. Protein Eng 1994;7:385-391. (Pubitemid 24063137) (Pubitemid 24063137)
166. De Moliner E, Brown NR, Johnson LN. Alternative binding modes of an inhibitor to two different kinases. Eur J Biochem 2003;270:3174-3181. (Pubitemid 36930182)
167. Golub AG, Yakovenko OY, Prykhod'ko AO, Lukashov SS, Bdzhola VG, Yarmoluk SM. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2. Biochim Biophys Acta 2008;1784:143-149.
168. Suzuki Y, Cluzeau J, Hara T, Hirasawa A, Tsujimoto G, Oishi S, Ohno H, Fujii N. Structure-activity relationships of pyrazine-based CK2 inhibitors: Synthesis and evaluation of 2,6-disubstituted pyrazines and 4,6-disubstituted pyrimidines. Arch Pharm 2008;341:554-561.
169. Nakaniwa T, Kinoshita T, Sekiguchi Y, Tada T, Nakanishi I, Kitaura K, Suzuki Y, Ohno H, Hirasawa A, Tsujimoto G. Structure of human protein kinase CK2alpha2 with a potent indazole-derivative inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009;65:75-79.
170. Tan YJ, Teng E, Ting AE. A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells. J Cancer Res Clin Oncol 2003;129:437-448.
171. Novac O, Guenier AS, Pelletier J. Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res 2004;32:902-915. (Pubitemid 38854693)
172. Soto J, Berman J. Treatment of new world cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 2006;100:S34-S40. (Pubitemid 44490170) (Pubitemid 44490170)
173. Golub AG, Yakovenko OY, Bdzhola VG, Sapelkin VM, Zien P, Yarmoluk SM. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem 2006;49:6443-6450. (Pubitemid 44657440)
174. Persson T, Yde CW, Rasmussen JE, Rasmussen TL, Guerra B, Issinger OG, Nielsen J. Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: Induction of growth arrest in MCF-7 cancer cells. Org Biomol Chem 2007;5:3963-3970. (Pubitemid 350205976)
175. Kuligowski J, Quintas G, Garrigues S, de la Guardia M. Determination of critical eluent composition for polyethylenglycols using on-line liquid chromatography-Fourier transform infrared spectrometry. Anal Chim Acta 2008;624:278-285.
176. Battistutta R, Sarno S, De Moliner E, Papinutto E, Zanotti G, Pinna LA. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem 2000;275:29618-29622. (Pubitemid 32043840)
177. Raaf J, Klopffleisch K, Issinger OG, Niefind K. The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin. J Mol Biol 2008;377:1-8.
178. De Moliner E, Moro S, Sarno S, Zagotto G, Zanotti G, Pinna LA, Battistutta R. Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J Biol Chem 2003;278:1831-1836. (Pubitemid 36801420)
179. Sarno S, Moro S, Meggio F, Zagotto G, Dal Ben D, Ghisellini P, Battistutta R, Zanotti G, Pinna LA. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther 2002;93:159-168. (Pubitemid 34615557)
180. Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, Sarno S, Donella-Deana A, Zagotto G, Rosolen A, Pinna LA, Meggio F, Moro S. Identification of ellagic acid as potent inhibitor of protein kinase CK2: A successful example of a virtual screening application. J Med Chem 2006;49:2363-2366.
181. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: A review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001;74:418-425.
182. Middleton E, Jr. Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol 1998;439:175-182.
183. Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 1995;33:1061-1080.
184. Madari H, Jacobs RS. An analysis of cytotoxic botanical formulations used in the traditional medicine of ancient Persia as abortifacients. J Nat Prod 2004;67:1204-1210. (Pubitemid 39149176)
185. Lacy A, O'Kennedy R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des 2004;10:3797-3811. (Pubitemid 39409871)
186. Kawase M, Sakagami H, Hashimoto K, Tani S, Hauer H, Chatterjee SS. Structure-cytotoxic activity relationships of simple hydroxylated coumarins. Anticancer Res 2003;23:3243-3246. (Pubitemid 36975419)
187. Finn G, Creaven B, Egan D. Modulation of mitogen-activated protein kinases by 6-nitro-7-hydroxycoumarin mediates apoptosis in renal carcinoma cells. Eur J Pharmacol 2003;481:159-167. (Pubitemid 37464965)
188. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E. Simple coumarins and analogues in medicinal chemistry: Occurrence, synthesis and biological activity. Curr Med Chem 2005;12:887-916. (Pubitemid 40443846)
189. Chilin A, Battistutta R, Bortolato A, Cozza G, Zanatta S, Poletto G, Mazzorana M, Zagotto G, Uriarte E, Guiotto A, Pinna LA, Meggio F, Moro S. Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: An integrate approach to elucidate the putative binding motif and explain structure-activity relationships. J Med Chem 2008;51:752-759. (Pubitemid 351304684)
190. Nie Z, Perretta C, Erickson P, Margosiak S, Lu J, Averill A, Almassy R, Chu S. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg Med Chem Lett 2008;18:619-623.
191. Nie Z, Perretta C, Erickson P, Margosiak S, Almassy R, Lu J, Averill A, Yager KM, Chu S. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2. Bioorg Med Chem Lett 2007;17:4191-4195.
192. Bettayeb K, Sallam H, Ferandin Y, Popowycz F, Fournet G, Hassan M, Echalier A, Bernard P, Endicott J, Joseph B, Meijer L. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Mol Cancer Ther 2008;7:2713-2724.
193. Prudent R, Lopez-Ramos M, Moucadel V, Barette C, Grierson D, Mouawad L, Florent JC, Lafanechere L, Schmidt F, Cochet C. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors. Biochim Biophys Acta 2008;1780:1412-1420.
194. Olgen S, Gotz C, Jose J. Synthesis and biological evaluation of 3-(substituted-benzylidene)-1,3-dihydro-indolin derivatives as human protein kinase CK2 and p60(c-Src) tyrosine kinase inhibitors. Biol Pharm Bull 2007;30:715-718. (Pubitemid 46570996)
195. Raaf J, Brunstein E, Issinger OG, Niefind K. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem Biol 2008;15:111-117. (Pubitemid 351253616)
196. Laudet B, Barette C, Dulery V, Renaudet O, Dumy P, Metz A, Prudent R, Deshiere A, Dideberg O, Filhol O, Cochet C. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. Biochem J 2007;408:363-373.
197. Laudet B, Moucadel V, Prudent R, Filhol O, Wong YS, Royer D, Cochet C. Identification of chemical inhibitors of protein-kinase CK2 subunit interaction. Mol Cell Biochem 2008;316:63-69.
198. Prudent R, Moucadel V, Laudet B, Barette C, Lafanechere L, Hasenknopf B, Li J, Bareyt S, Lacote E, Thorimbert S, Malacria M, Gouzerh P, Cochet C. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem Biol 2008;15:683-692. (Pubitemid 351957909)